CervoMed Inc. (CRVO)
| Market Cap | 31.85M -65.3% |
| Revenue (ttm) | 2.09M -58.9% |
| Net Income | -30.04M |
| EPS | -3.27 |
| Shares Out | 9.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 119,643 |
| Open | 3.740 |
| Previous Close | 3.760 |
| Day's Range | 3.350 - 3.740 |
| 52-Week Range | 3.350 - 13.130 |
| Beta | -4.47 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+568.61%) |
| Earnings Date | May 15, 2026 |
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant... [Read more]
Financial Performance
In 2025, CervoMed's revenue was $4.01 million, a decrease of -58.86% compared to the previous year's $9.74 million. Losses were -$26.97 million, 65.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRVO stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 568.61% from the latest price.
News
CervoMed presents neflamapimod MRI data
CervoMed (CRVO) presented placebo-controlled magnetic resonance imaging analyses providing evidence that neflamapimod may increase the size and enhance the function of the basal forebrain in patients ...
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design
CervoMed Transcript: The 38th Annual Roth Conference
Significant progress was reported in developing a targeted therapy for DLB, with strong phase II results and a de-risked phase III trial set to launch by year-end. Biomarker-driven patient selection and updated manufacturing processes are expected to enhance efficacy and market potential.
CervoMed’s neflamapimod shows efficacy in dementia with DLB
CervoMed (CRVO) announced that, at the AD/PD 2026 Conference in Copenhagen, Denmark, investigators will present new analyses from the Phase 2b RewinD-LB clinical trial of neflamapimod, being developed...
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit wit...
CervoMed price target lowered to $11 from $19 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $11 from $19 and keeps a Buy rating on the shares. The company’s Q4/FY25 financial results…
CervoMed price target raised to $21 from $15 at Chardan
Chardan raised the firm’s price target on CervoMed (CRVO) to $21 from $15 and keeps a Buy rating on the shares. The neflamapimod program is fully back on track following…
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
Believes its cash, cash equivalents, and marketable securities on hand will enable the company to fund its planned operating expenses and capital expenditure for approximately six months from now. “Ce...
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in...
CervoMed announces presentations at AP/PD 2026 scientific conference
CervoMed (CRVO) announced that neflamapimod, an oral, small molecule, drug candidate targeting critical disease processes underlying degenerative disorders of the brain, will be featured in an oral pr...
CervoMed completes Phase 1 volunteer study for neflamapimod
CervoMed (CRVO) announced that it has successfully completed a Phase 1 healthy volunteer study designed to evaluate the pharmacokinetics, PK, of drug product containing only a new, stable crystal form...
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stab...
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
CervoMed (CRVO) announced that neflamapimod, an oral small molecule drug candidate targeting critical disease processes underlying degenerative disorders of the brain, has been selected for inclusion ...
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targe...
CervoMed initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Pete Stavropoulos initiated coverage of CervoMed (CRVO) with an Overweight rating and no price target CervoMed has generated “intriguing” data in two Phase 2 studies for nefl...
CervoMed’s neflamapimod shows efficacy in slowing dementia
Cervomed (CRVO) announced that, in a late-breaking oral session at the 18th Clinical Trials on Alzheimer’s Disease Conference in San Diego, California, clinical investigators shared the full results o...
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology
CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod
CervoMed (CRVO) has shared new data from the Phase 2b RewinD-LB trial demonstrating neflamapimod treatment led to a significant reduction in the widely used neurodegeneration biomarker plasma GFAP and...
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
1st of two presentations with results from Phase 2b study of neflamapimod at the 18 th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB
CervoMed price target lowered to $19 from $20 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $19 from $20 and keeps a Buy rating on the shares. In the wake of Q3…
CervoMed reports Q3 EPS (84c), consensus (56c)
Reports Q3 revenue $322.6k, consensus $1.3M. “In the past nine months, CervoMed (CRVO) has made remarkable strides, culminating in our recent alignment with the FDA on key aspects of the…
CervoMed upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju upgraded CervoMed (CRVO) to Buy from Neutral with a $25 price target after the company received written feedback from the FDA aligning on key aspects…
CervoMed announces FDA alignment on neflamapimod registration path
CervoMed (CRVO) has received written feedback from the U.S. Food and Drug Administration aligning on key aspects of CervoMed’s proposed Phase 3 clinical trial of neflamapimod, an oral, small molecule,...